Based on the loss of calcium-current inhibition found in vitro in GNAO1 mutants, resulting from altered Gαo -mediated signaling induced by norepinephrine, Nakamura et al. suggested the use of selective calcium-channel blockers or the use of the high-voltage activated calcium channels modulator topiramate to alleviate epilepsy in patients with GNAO1 mutations [2]. The gene discussed is GNAO1; the disease is epilepsy.